Core Insights - Prenetics Global Limited reported a significant increase in total revenue, surging 568% year-over-year to $23.6 million in Q3 2025, with a gross profit of $14.0 million, reflecting a 631.2% increase compared to Q3 2024 [14][25][9] - The company's IM8 brand achieved record monthly revenue of $9 million in October 2025, marking a 36% month-over-month growth from September [4][2] - IM8 is projected to reach $180 to $200 million in revenue for FY 2026, translating to approximately $25 million in monthly revenue or $300 million in annual recurring revenue (ARR) by the end of 2026 [21][11] Financial Performance - Q3 2025 financial highlights include a quarterly revenue of $23.6 million, a gross margin of 60%, and an adjusted EBITDA loss of $(2.1) million, improving from $(4.5) million in Q1 2025 [14][9][10] - The company reported a total of 420,000 customer purchases across 31 countries, with international markets contributing 56.5% of IM8's revenue [5][4] - The average order value for new customers increased to $150 in October 2025, up 36% from the previous month [6][8] Strategic Developments - Prenetics completed a $44 million equity offering in October 2025, attracting strategic investors, which positions the company for accelerated global expansion [3][10] - The company maintains a strong balance sheet with approximately $120 million in total liquidity and zero debt, allowing for aggressive scaling without dilutive capital needs [10][15] - Prenetics is executing a strategic review of non-core assets to focus on its highest-growth unit, IM8, following the successful divestiture of ACT Genomics [18][19] Market Positioning - IM8 is recognized for having the fastest growth trajectory in the global supplements industry, achieving $108 million in ARR within 11 months of launch [25][2] - The company is also pioneering a dual-engine strategy by integrating Bitcoin as a strategic treasury asset, currently holding 387 BTC valued at approximately $41 million [16][26] - Prenetics aims to replicate the success of direct-to-consumer brands like Hims & Hers, leveraging strong unit economics and a subscription-based revenue model [11][21]
Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History